Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch

Phase 3

Completed

Conditions: Allergic Rhinoconjunctivitis

Interventions: Drug: Depiquick Birch (DPG103)
Drug: Placebo

First Posted Date: 2013-07-19

Last Posted Date: 2017-03-22

Lead Sponsor: Novartis

Target Recruit Count: 202

Registration Number: NCT01902992

Locations: 🇩🇪
Novartis Investigative Site, Witten, Germany

Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: Fluvirin(TIVf)
Biological: Agriflu (TIV)

First Posted Date: 2013-06-03

Last Posted Date: 2014-10-01

Lead Sponsor: Novartis

Target Recruit Count: 2902

Registration Number: NCT01867021

Locations: 🇨🇿
Site 71 - Ordinace všeobecného lékaře, Kbel 163, Benátky nad Jizerou, Czech Republic
🇨🇿
Site 70 - Vaccination and Travel Medicine Centre, Poliklinika II., Bratri Stefanu 895, Hradec Kralove, Czech Republic
🇵🇭
Site 61 - Research Institute for Tropical Medicine DOH Compound, Filinvest Corporate City, Alabang Muntinlupa City, Philippines

and more 22 locations

Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China

Completed

Conditions: Kidney Transplantation

First Posted Date: 2013-02-22

Last Posted Date: 2014-06-18

Lead Sponsor: Novartis

Target Recruit Count: 1500

Registration Number: NCT01796639

Locations: 🇨🇳
The 309th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China
🇨🇳
Beijing Chaoyang Hospital, Beijing, Beijing, China
🇨🇳
Peking University First Hospital, Beijing, Beijing, China

and more 15 locations

Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies

Completed

Conditions: Hepatitis C

Interventions: Drug: Eltrombopag

First Posted Date: 2012-10-29

Last Posted Date: 2016-04-08

Lead Sponsor: Novartis

Target Recruit Count: 22

Registration Number: NCT01715779

Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain

Phase 4

Completed

Conditions: Ankle Sprain

Interventions: Drug: diclofenac potassium 25 mg tablet
Drug: placebo

First Posted Date: 2012-08-16

Last Posted Date: 2014-04-17

Lead Sponsor: Novartis

Target Recruit Count: 100

Registration Number: NCT01666197

Locations: 🇩🇪
Investigator, Köln, Germany

Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup in Patients Suffering a URTI

Phase 3

Completed

Conditions: Upper Respiratory Infections

Interventions: Drug: IFF flavor 316 282, Paracetamol, Pseudoephedrine

First Posted Date: 2012-04-27

Last Posted Date: 2013-08-07

Lead Sponsor: Novartis

Target Recruit Count: 56

Registration Number: NCT01586962

Locations: 🇨🇦
Algorithme Pharma, Montreal, Quebec, Canada

Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)

Phase 3

Completed

Conditions: Upper Respiratory Infections

Interventions: Drug: IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin

First Posted Date: 2012-04-12

Last Posted Date: 2013-11-11

Lead Sponsor: Novartis

Target Recruit Count: 51

Registration Number: NCT01576809

Locations: 🇨🇦
Algorithme Pharma, Montreal, Quebec, Canada

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

Phase 1

Completed

Conditions: End Stage Renal Disease

Interventions: Drug: Aliskiren

First Posted Date: 2012-04-02

Last Posted Date: 2012-04-02

Lead Sponsor: Novartis

Target Recruit Count: 12

Registration Number: NCT01568775

Locations: 🇩🇪
Charité Universitätsmedizin, Berlin, Germany

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India

Phase 3

Completed

Conditions: Bacterial Meningitis

Interventions: Biological: Meningococcal ACWY conjugate vaccine

First Posted Date: 2012-03-08

Last Posted Date: 2018-10-09

Lead Sponsor: Novartis

Target Recruit Count: 180

Registration Number: NCT01547715

Locations: 🇮🇳
Osmania Medical College Ethics Commitee, Niloufer Hospital, Hyderabad, Andrapradesh, India
🇮🇳
Bharati Vidyapeeth University Institutional Ethics Commitee, Katraj, Dhankawadi, India
🇮🇳
Padmasree Dr. D.Y Patil medical College, Pune, Maharashtra, India

and more 1 locations

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Phase 3

Completed

Conditions: Meningococcal Meningitis
Typhoid
Japanese Encephalitis
Meningococcal Disease
Yellow Fever
Rabies

Interventions: Biological: Rabies Vaccine
Biological: Typhoid Vi Polysaccharide Vaccine
Biological: Japanese Encephalitis Vaccine
Biological: Yellow Fever Vaccine
Biological: MenACWY-CRM Vaccine

First Posted Date: 2011-11-08

Last Posted Date: 2014-03-11

Lead Sponsor: Novartis

Target Recruit Count: 552

Registration Number: NCT01466387

Locations: 🇨🇿
Centrum ockovani a cestovni mediciny (Vaccination and Travel Medicine Centre) Poliklinika II, Bratri Stefanu 895, Hradec Kralove, Czech Republic
🇩🇪
Berliner Centrum Fur Reise und Tropenmedizin, Jaegerstrasse 67-69, Berlin, Germany
🇩🇪
University of Munich Georgenstr.5, Muenchen, Germany

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy